ProfileGDS5678 / 1450477_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 27% 27% 27% 26% 29% 51% 36% 27% 26% 27% 27% 27% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6578527
GSM967853U87-EV human glioblastoma xenograft - Control 22.6169927
GSM967854U87-EV human glioblastoma xenograft - Control 32.6211327
GSM967855U87-EV human glioblastoma xenograft - Control 42.5482126
GSM967856U87-EV human glioblastoma xenograft - Control 52.6203329
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3390851
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8707636
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5946827
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5795826
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6056127
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6024827
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5853827
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.61327
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.60827